Reminder: Invitation to Roche’s Full Year Results 2022 Presentation Donnerstag, 26. Januar 2023 - 10:22

Roche will publish its Full Year Results for 2022 prior to the opening of the Swiss Stock Exchange on Thursday, 2 February 2023.

07:00 CET / 06:00 GMT / 01:00 AM EST / 10:00 PM PST (evening before)

Release will be e-mailed and posted on the Roche IR website > click here
Presentation slides will be posted on the Roche IR website > click here

The webinar will start with presentations by senior management, followed by a Q&A session.

Presenters:

• Severin Schwan, CEO Roche Group
• Thomas Schinecker, CEO Roche Pharmaceuticals ad interim
• Matt Sause, CEO Roche Diagnostics
• Alan Hippe, Chief Financial and IT Officer

We would like to invite all interested parties to participate in the webinar and to pre-register for the event here*

Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com.

A replay of the webcast will be available via > ir.roche.com

*privacy notice

Best regards,

Bruno Eschli
Head of Investor Relations

Roche Investor Relations

Dr. Bruno Eschli

Phone: +41 61 68-75284

e-mail: bruno.eschli@roche.com

Dr. Sabine Borngräber

Phone: +41 61 68-88027

e-mail: sabine.borngraeber@roche.com

Dr. Birgit Masjost

Phone: +41 61 68-84814

e-mail: birgit.masjost@roche.com

Dr. Gerard Tobin

Phone: +41 61 68-72942

e-mail: gerard.tobin@roche.com

Investor Relations North America

Loren Kalm

Phone: +1 650 225 3217

e-mail: kalm.loren@gene.com